<DOC>
	<DOCNO>NCT02457416</DOCNO>
	<brief_summary>The purpose study identify prognostic marker possible success rate tolerance induction peanut allergens child allergic peanut .</brief_summary>
	<brief_title>Take Away Food Allergy ; Inducing Tolerance Children Allergic Peanut</brief_title>
	<detailed_description>The study open randomize control study oral immunotherapy include 60 child ( 40 active treatment , 20 control ) primary peanut allergy . The study 4 phase : 1 : inclusion/randomization include double blind placebo control food Challenge 2 : bi weekly up-dosing maintenance dose 48 week , 3 : maintenance period 3 year 4 : 1 year follow end treatment . Clinical parameter well immunological ( serological cellular ) record inclusion , 3 month up-dosing , end up-dosing , 1 3 year maintenance treatment 3 12 year follow .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<criteria>Positive skin prick test IgE peanut Age 515 yr Primary peanut allergy verify objective symptom DBPCFC dose 3 mg peanut potein Non control asthma ( asthma control test , ACT ) Allergy/intolerance ingredient vehicle use peanut DBPCFC Current previous allergen specific immunotherapy Cardiac disease increase risk serious anaphylaxis Severe atopic skin disease Diabetes mellitus Severe disease interfere adherence study protocol</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Peanut allergy</keyword>
	<keyword>Oral immunotherapy</keyword>
</DOC>